Dubai-based solar developer Phanes Group has said it expects to increase its global installed capacity of solar energy by 500 megawatts over the next two years. The plan follows General Energy ...

Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the ...

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the ...

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the ...

Phanes Group’s Solar Incubator was initiated in 2017 to tackle the issue head-on, fostering local innovation and investment by providing local solar PV developers with the funding and commercial and ...

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the U.S.

Peluntamig (PT217), a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and ...

Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective first-line (1L) treatment in patients with CLDN18.2 ...